Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (8768)	2/14/2002 11:45:09 PM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

<font color=red>Merck's Vioxx Label May Have Heart Warning Added, Analyst Says By Joseph Richter Whitehouse Station, New Jersey, Feb. 14 (Bloomberg) -- Merck & Co. may add a cardiovascular warning to the U.S. label of its Vioxx painkiller and an experimental follow-up drug, Arcoxia, which could put these drugs at a disadvantage to rivals, an analyst said. The U.S. Food and Drug Administration may require Merck to include information about higher risk of heart attacks for Vioxx patients compared with those on an older painkiller, said Tim Anderson of Prudential Securities. A decision may come within a few weeks, he said. Merck and Pharmacia Corp., maker of the Vioxx rival, Celebrex, are neck-and-neck in a race for new prescriptions for the painkillers. A warning on the Vioxx label might give an edge to Pharmacia and Pfizer Inc., which helps market Celebrex, Anderson said. ``We think it could be a slight net win'' for Pharmacia and Pfizer, he said in a report. In a report on expected label changes for Celebrex and Vioxx, Anderson said that the FDA also may be looking at whether Merck's successor to Vioxx, a drug called Arcoxia, has a cardiovascular risk. The FDA may ask a committee of expert advisers from outside of the agency to review Arcoxia at a May meeting, Anderson said in a report. ``This would not necessarily mean the end of Arcoxia from a commercial perspective, but having a compromised label would clearly give (Pharmacia and Pfizer) more ammunition to reinforce the (cardiovascular) safety of their products,'' Anderson said. Merck declined to comment on whether it had been notified about an Arcoxia panel. ``It's not appropriate for us to comment at all,'' said Chris Fanelle, a Merck spokeswoman. ``The decision to consult an advisory committee is up to the FDA.'' Shares of Whitehouse Station, New Jersey-based Merck fell 89 cents to $59.69. Shares of Peapack, New Jersey-based Pharmacia shares rose 41 cents to $40.45.

To: axial who wrote (8768)	2/15/2002 7:26:25 AM
From: TheBusDriver	Respond to of 14101

<<HC wouldn't allow WF10 trials. HC is (in effect) blocking Pennsaid, while it holds the company up for ransom, and leaks the results before the market finds out (twice). No corruption there! HC quickly whips inferior products through to approval (ahead of the FDA), and leaves DMX twisting in the wind. Yup. No corruption, there.>> You know I was studying this chart and considering posting it here. I was suspect about the dip in the index coinciding with the HC denial to DMX but chided myself for having a suspicious mind. Now I see I am not the only one. If, in fact, the Biotech index is reversing after hitting a brick wall at RSI=50, as this chart indicates is possible, DMX might be in for a rough ride for the next few days. While DMX did not track the index directly there is enough correlation for me to have cancelled my low-ball bid to wait for the smoke to clear. Hope I am wrong! BTW, Excellent post! bigcharts.marketwatch.com Wayne (crossed fingers)